Larimar Therapeutics, Inc. Common Stock (LRMR) is a publicly traded Healthcare sector company. As of May 21, 2026, LRMR trades at $3.47 with a market cap of $336.58M and a P/E ratio of 0.00. LRMR moved +5.71% today. Year to date, LRMR is +5.06%; over the trailing twelve months it is +71.36%. Its 52-week range spans $1.61 to $9.50. Analyst consensus is strong buy with an average price target of $16.00. Rallies surfaces LRMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LRMR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LRMR recently traded at $3.47. Market cap is $336.58M. P/E ratio is 0.00. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $3.47 |
| Market Cap | $336.58M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.50 |
| 52-Week Low | $1.61 |
| Volume | 553 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-165.67M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-165.67M | $0.00 |
| 2024 | $0 | $-80.60M | $-1.32 |
| 2023 | $0 | $-36.95M | $-0.84 |
| 2022 | $0 | $-35.35M | $-1.37 |
5 analysts cover LRMR: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.00.